If successful, we believe we have the potential to transform outcomes for tens of thousands of patients each year.
TargImmune’s novel Ta:RNA™ platform harnesses the body’s powerful antiviral defence responses to selectively target and destroy cancer cells. This unique technology and innovative therapeutic approach have the potential to transform outcomes for cancer patients, whether used alone or in combination with existing treatments.
Despite significant advances in cancer treatments over the past decades, there are still gaps across classes of anti-cancer therapies. Whether they’re driving resistance, lack efficacy against ‘cold’ tumours, fail to deal with heterogeneous tumours, or show efficacy in only small patient populations, cancer patients could benefit from a new approach.
TargImmune’s therapeutics are the first in a new class - known as targeted apoptosis and immune modulators (TAIMs) - that addresses these limitations.